The Nordic Diltiazem Study (NORDIL). A Prospective Intervention Trial of of Calcium Antagonist Therapy in Hypertension

References

• Kannel W B. Role of blood pressure in cardiovascular morbidity and mortality. Prog Cardiovasc Dis 1974; 7: 5–24
   Web of Science ®Google Scholar
• MacMahon S W, Cutler J A, Furberg C D, Payne G H. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized trials. Prog Cardiovasc Dis 1986; 29: 99–119, (Suppl)
   PubMed Web of Science ®Google Scholar
• Editorial. New trials in older hypertensives. Lancet 1991; 338: 1299–1300
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Lindholm L, Hansson L, Scherstén B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program. JAMA 1991; 265: 3255–64
   PubMed Web of Science ®Google Scholar
• MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal result. BMJ 1992; 304: 405–12
   PubMed Web of Science ®Google Scholar
• The 1992 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1993; 153: 154–83
   PubMed Web of Science ®Google Scholar
• Workshop-Individualised antihypertensive treatment. Recommendations from a consensus meeting arranged by the Swedish Medical Products Agency. 1990; 3
   Google Scholar
• The 1993 Guidelines for the management of mild hypertension: memorandum from WHO/ISH meeting. Blood Pressure 1993; 2: 86–100
   PubMedGoogle Scholar
• The CAPPP group. The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. J Hypertens 1990; 8: 985–990
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Hansson L, Lindholm L H. STOP-Hypertension 2-A prospective intervention trial of “newer” versus “older” treatment alternatives in essential hypertension. Blood Pressure 1993; 2: 137–42
   Google Scholar
• The HOT Study Group. The hypertension optimal treatment study (The HOT-study). Blood Pressure 1993; 2: 62–8
   PubMedGoogle Scholar
• Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986; 38: 321–416
   PubMed Web of Science ®Google Scholar
• Kiowski W, Bolli P, Erne P, Hulthén UL, Müller FB, Bühler FR. Hemodynamic and counterregulatory effects of calcium antagonists in hypertension. J Cardiovasc Pharmacol 1988; 12: 539–43, (Suppl 6)
   Web of Science ®Google Scholar
• Lund-Johansen P, Omvik P. Effect of long-term diltiazem treatment on central haemodynamics and exercise endurance in essential hypertension. Eur Heart J 1990; 11: 543–51
   PubMed Web of Science ®Google Scholar
• Leonetti G, Rupoli L, Gradnik R, Zanchetti A. Effects of a low sodium diet on antihypertensive and natriuretic responses to acute administration of nifedipine. J Hypertension 1987; 5: S57–60, (Suppl 4)
   PubMed Web of Science ®Google Scholar
• Loutzenhiser R D, Epstein M. Renal hemodynamic effects of calcium antagonists. J Cardiovasc Pharmacol 1988; 12: S48–52, (Suppl 6)
   Web of Science ®Google Scholar
• Scriabine A. Comparative pharmacology of 1.4 dihydropyridines and other Ca++ channel ligands. J Cardiovasc Pharmacol 1987; 9: S3–7, (Suppl 1)
   Web of Science ®Google Scholar
• Chaffman M, Brogden R N. Diltiazem a review of its pharmacological properties and therapeutic efficacy. Drugs 1985; 29: 387–454
   PubMed Web of Science ®Google Scholar
• Pool P E, Seagren S C, Salel A F. Effects of diltiazem on serum lipids, exercise performance and blood pressure; randomized, double-blind placebo-controlled evaluation for systemic hypertension. Am J Cardiol 1985; 56: 86H–91
   PubMed Web of Science ®Google Scholar
• Pool P E, Massie B M, Venkataraman K. Diltiazem as monotherapy for systemic hypertension: a multicenter, randomized, placebo-controlled trial. Am J Cardiol 1986; 57: 212–7
   PubMed Web of Science ®Google Scholar
• Pool P E, Herron J M, Rosenblatt S. Metabolic effects of antihypertensive therapy with a calcium antagonist. Am J Cardiol 1988; 62: 109G–13
   Web of Science ®Google Scholar
• Nikkilä M, Inkovaara J, Heikkinen J, Olsson S-O. Antihypertensive effects of diltiazem in a slow release formulation in patients with mild to moderate essential hypertension. Am J Cardiol 1989; 63: 1227–30
   PubMed Web of Science ®Google Scholar
• Andrén L, Höglund P, Dotevall A, Eggertsen R, Svensson A, Olsson S-O, Wadenvik H. Diltiazem in hypertensive patients with type II diabetes mellitus. Am J Cardiol 1988; 62: 114G–120
   Web of Science ®Google Scholar
• Frishman W H, Zawada ET, Jr, Smith L K. Comparison of hydrochlorothiazide and sustained-release diltiazem for mild to moderate systemic hypertension. Am J Cardiol 1987; 59: 615–23
   PubMed Web of Science ®Google Scholar
• Massie B, MacCarthy E P, Ramanathan K B. Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide. Ann Intern Med 1987; 107: 150–7
   PubMed Web of Science ®Google Scholar
• Weier M R, Josselson J, Giard M I. Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. Am J Cardiol 1987; 60: 361–411
   Web of Science ®Google Scholar
• Trimarco B, DeLuca N, Riccardelli B. Diltiazem in the treatment of mild to moderate essential hypertension: comparison with metoprolol in cross-over double-blind trial. J Clin Pharmacol 1984; 24: 218–27
   PubMed Web of Science ®Google Scholar
• Hedner T, Thulin T, Gustafsson S, Olsson S-O. For the Swedish Diltiazem-Metoprolol Multicentre Study Group: A comparison of diltiazem and metoprolol in hypertension. Eur J Clin Pharmacol 1990; 39: 427–33
   PubMed Web of Science ®Google Scholar
• Thulin T, Hedner T, Gustafsson S, Olsson S-O. Diltiazem compared with metoprolol as add-on-therapies to diuretics in hypertension. J Hum Hypertens 1991; 5: 107–14
   PubMed Web of Science ®Google Scholar
• Wolfson P, Abernethy D, DiPette D, Zusman R. Diltiazem and captopril alone or in combination for treatment of mild to moderate systemic hypertension. Am J Cardiol 1988; 62: 103G–8
   PubMed Web of Science ®Google Scholar
• Schulte K-L, Meyer-Sabellek W A, Haertenberger A. Antihypertensive and metabolic effects of diltiazem and nifedipine. Hypertension 1986; 8: 859–65
   PubMed Web of Science ®Google Scholar
• Pool P E, Seagren S C, Salel A F. Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized double-blind placebo-controlled evaluation for systemic hypertension. Am J Cardiol 1985; 56: 86H–91
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol. Results from a randomized, double-blind, study with parallel group. J Hypertens 1989; 7: 551–9
   PubMed Web of Science ®Google Scholar
• Hedner T, Samulesson O, Lindholm L. Effects of antihypertensive therapy on glucose tolerance: focus of calcium antagonists. J Intern Med 1991; 229: 101–11, (Suppl 2)
   Web of Science ®Google Scholar
• Dahlöf C, Hedner T, Gustafsson S, Olsson S-O. Effects of diltiazem and metoprolol on blood pressure adverse symptoms and general well-being. Eur J Clin Pharmacol 1991; 40: 453–60
   PubMed Web of Science ®Google Scholar
• Bauer J H, Reams G. Short- and long-term effects of calcium entry blockers on the kidney. Am J Cardiol 1987; 59: 66A–71
   PubMed Web of Science ®Google Scholar
• Szlachcic J, Tubau J, Massie B M. Diltiazem reduces left ventricular mass but does not change diastolic filling in mild hypertension. J Am Coll Cardiol 1988; 11: 82A
   Google Scholar
• Moss A J, Oakes Rubison D. Effects of diltiazim on long-term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. Am J Cardiol 1991; 68: 429–33
   PubMed Web of Science ®Google Scholar
• Sunderrajan S, Reams G, Bauer J H. Renal effects of diltiazem in primary hypertension. Hypertension 1986; 8: 238–42
   PubMed Web of Science ®Google Scholar
• Sunderrajan S, Reams G, Bauer J H. Long-term renal effects of diltiazem in essential hypertension. Am Heart J 1987; 114: 383–8
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients-a metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–110
   PubMed Web of Science ®Google Scholar
• Dahlöf B. Structural cardiovascular changes in essential hypertension. Studies on the effect of antihypertensive therapy. Blood Pressure 1992; 1: 1–75, (Suppl 6)
   Google Scholar
• Matherson B J, Reda D J, Cushman W C. Single-drug therapy for hypertension in men. New Engl J Med 1993; 328: 914–21
   PubMed Web of Science ®Google Scholar
• Hedner T. Calcium antagonists: spectrum of side effects and drug interactions. Acta Pharmacol Toxicol 1986; 58: 119–30, (Suppl II)
   PubMedGoogle Scholar
• Statistical Abstract of Sweden. Statistics Sweden. 1991
   Google Scholar
• Isles C G, Walker L M, Beevers D G. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986; 4: 141–56
   PubMed Web of Science ®Google Scholar
• Causes of death 1988. Statistics, Sweden 1991
   Google Scholar
• Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded Endpoint (PROBE) study: a novel design for intervention trials. Blood Pressure 1992; 1: 113–9
   PubMedGoogle Scholar